Inactive Instrument

News Adamas Pharmaceuticals, Inc.

Equities

ADMS

US00548A1060

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Adamas Pharmaceuticals : Completion of Acquisition or Disposition of Assets - Form 8-K	21-11-24	PU
ADAMAS PHARMACEUTICALS INC : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	21-11-24	AQ
Adamas Pharmaceuticals, Inc. Announces Management Changes	21-11-24	CI
Adamas Pharmaceuticals, Inc.(NasdaqGM:ADMS) dropped from NASDAQ Composite Index	21-11-24	CI
Adamas Pharmaceuticals, Inc.(NasdaqGM:ADMS) dropped from S&P TMI Index	21-11-24	CI
Adamas Pharmaceuticals, Inc.(NasdaqGM:ADMS) dropped from S&P Global BMI Index	21-11-24	CI
Supernus Pharmaceuticals, Inc. completed the acquisition of Adamas Pharmaceuticals, Inc. from Mohr Davidow Ventures and others.	21-11-23	CI
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Adamas Pharmaceuticals Tender Offer	21-11-23	AQ
Northland Downgrades Adamas Pharmaceuticals to Market Perform From Outperform; Price Target is $8.50	21-11-17	MT
Adamas: Q3 Earnings Snapshot	21-11-11	AQ
ADAMAS PHARMACEUTICALS INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	21-11-10	AQ
Adamas Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-10	CI
North American Morning Briefing : Stock Futures -3-	21-10-13	DJ
ADAMAS PHARMACEUTICALS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Adamas Pharmaceuticals, Inc. - ADMS	21-10-12	BU
ADAMAS PHARMACEUTICALS : SVB Leerink Downgrades Adamas Pharmaceuticals to Market perform From Outperform, Adjusts Price Target to $8 From $6	21-10-12	MT
ADAMAS PHARMACEUTICALS : JMP Securities Downgrades Adamas Pharmaceuticals to Market Perform from Market Outperform	21-10-12	MT
ADAMAS PHARMACEUTICALS : Piper Sandler Downgrades Adamas Pharmaceuticals to Neutral from Overweight, Adjusts Price Target to $8 from $7	21-10-12	MT
ADAMAS PHARMACEUTICALS : HC Wainwright Downgrades Adamas Pharmaceuticals to Neutral From Buy, Trims Price Target to $9.10 From $10	21-10-12	MT
Adamas Pharmaceuticals : Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product Portfolio - Form 8-K	21-10-12	PU
ADAMAS PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)	21-10-12	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Adamas Pharmaceuticals, Inc.

Equities

ADMS

US00548A1060

Summary

Filters